Adicet Bio Appoints Michael Grissinger to the Board of Directors
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has appointed Michael Grissinger to its Board of Directors. Grissinger brings over 40 years of pharmaceutical business development and strategic transaction experience, including more than two decades at Johnson & Johnson where he served as Vice President and Head of Worldwide Pharmaceutical Licensing and Corporate Development.
During his tenure at Johnson & Johnson, Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was a member of the Immunology R&D/Commercial leadership team. Prior to J&J, he spent 12 years at Ciba-Geigy in finance, marketing, and business development roles. He currently serves on the board of Aprea Therapeutics and three private biotech companies.
Adicet Bio (Nasdaq: ACET), un'azienda biotecnologica in fase clinica specializzata in terapie con cellule T gamma delta allogeniche, ha nominato Michael Grissinger nel suo Consiglio di Amministrazione. Grissinger porta con sé oltre 40 anni di esperienza nello sviluppo commerciale farmaceutico e nelle transazioni strategiche, inclusi più di vent'anni presso Johnson & Johnson, dove ha ricoperto il ruolo di Vicepresidente e Responsabile del Licensing Farmaceutico Mondiale e dello Sviluppo Aziendale.
Durante il suo incarico in Johnson & Johnson, Grissinger ha guidato il gruppo di Sviluppo Commerciale e Licensing nell'area terapeutica Immunologia ed è stato membro del team di leadership R&D/Commerciale dell’Immunologia. Prima di J&J, ha lavorato per 12 anni in Ciba-Geigy in ruoli di finanza, marketing e sviluppo commerciale. Attualmente siede nel consiglio di Aprea Therapeutics e di tre aziende biotecnologiche private.
Adicet Bio (Nasdaq: ACET), una empresa biotecnológica en etapa clínica enfocada en terapias con células T gamma delta alogénicas, ha nombrado a Michael Grissinger en su Junta Directiva. Grissinger aporta más de 40 años de experiencia en desarrollo comercial farmacéutico y transacciones estratégicas, incluyendo más de dos décadas en Johnson & Johnson, donde fue Vicepresidente y Jefe de Licencias Farmacéuticas Mundiales y Desarrollo Corporativo.
Durante su tiempo en Johnson & Johnson, Grissinger lideró el grupo de Desarrollo Comercial y Licencias del Área Terapéutica de Inmunología y formó parte del equipo directivo de I+D y Comercialización en Inmunología. Antes de J&J, trabajó 12 años en Ciba-Geigy en finanzas, marketing y desarrollo comercial. Actualmente forma parte del consejo de Aprea Therapeutics y de tres empresas biotecnológicas privadas.
Adicet Bio (나스닥: ACET)는 동종 감마 델타 T 세포 치료제에 집중하는 임상 단계의 바이오테크 회사로, 마이클 그리싱어(Michael Grissinger)를 이사회에 임명했습니다. 그리싱어는 제약 사업 개발 및 전략적 거래 분야에서 40년 이상의 경력을 보유하고 있으며, 존슨앤드존슨(Johnson & Johnson)에서 20년 넘게 부사장 겸 전 세계 제약 라이선싱 및 기업 개발 책임자로 근무했습니다.
존슨앤드존슨 재직 기간 동안 그리싱어는 면역학 치료 분야 사업 개발 및 라이선싱 그룹을 이끌었으며, 면역학 연구개발 및 상업화 리더십 팀의 일원이었습니다. J&J 이전에는 시바-가이기(Ciba-Geigy)에서 12년간 재무, 마케팅 및 사업 개발 역할을 수행했습니다. 현재는 Aprea Therapeutics와 세 개의 비상장 바이오텍 회사 이사회 멤버로 활동 중입니다.
Adicet Bio (Nasdaq : ACET), une société biotechnologique en phase clinique spécialisée dans les thérapies cellulaires T gamma delta allogéniques, a nommé Michael Grissinger à son conseil d'administration. Grissinger apporte plus de 40 ans d'expérience en développement commercial pharmaceutique et en transactions stratégiques, dont plus de vingt ans chez Johnson & Johnson, où il a occupé le poste de vice-président et responsable mondial des licences pharmaceutiques et du développement corporatif.
Au cours de son mandat chez Johnson & Johnson, Grissinger a dirigé le groupe de développement commercial et de licences dans le domaine thérapeutique de l'immunologie et faisait partie de l'équipe de direction R&D/Commerciale en immunologie. Avant J&J, il a passé 12 ans chez Ciba-Geigy dans des fonctions financières, marketing et développement commercial. Il siège actuellement au conseil d'administration d'Aprea Therapeutics ainsi que de trois entreprises biotechnologiques privées.
Adicet Bio (Nasdaq: ACET), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf allogene Gamma-Delta-T-Zelltherapien spezialisiert hat, hat Michael Grissinger in seinen Vorstand berufen. Grissinger bringt über 40 Jahre Erfahrung in der pharmazeutischen Geschäftsentwicklung und strategischen Transaktionen mit, darunter mehr als zwei Jahrzehnte bei Johnson & Johnson, wo er als Vizepräsident und Leiter der weltweiten Pharma-Lizenzierung und Unternehmensentwicklung tätig war.
Während seiner Zeit bei Johnson & Johnson leitete Grissinger die Geschäftsentwicklung und Lizenzierung im Immunologie-Therapiebereich und war Mitglied des Führungs-Teams für Forschung & Entwicklung sowie Vertrieb im Bereich Immunologie. Vor seiner Zeit bei J&J arbeitete er 12 Jahre bei Ciba-Geigy in den Bereichen Finanzen, Marketing und Geschäftsentwicklung. Derzeit sitzt er im Vorstand von Aprea Therapeutics und drei privaten Biotech-Unternehmen.
- Addition of seasoned pharmaceutical executive with 40+ years of business development experience
- Strategic expertise in immunology and pharmaceutical licensing
- Strong industry connections from leadership roles at Johnson & Johnson
- Experience in M&A and business development could support future strategic transactions
- None.
--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions--
“We are honored to welcome Michael to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “His extensive operational and business development experience across the global pharmaceutical industry, especially his deep expertise in immunology, brings a wealth of knowledge and invaluable strategic insight to Adicet. Michael’s notable accomplishments in driving business and commercial success will be instrumental in shaping the next stage of our growth as we continue to advance our gamma delta T cell platform for the treatment of autoimmune and solid tumor indications.”
Mr. Grissinger spent more than two decades at Johnson & Johnson. During his Johnson & Johnson tenure, Mr. Grissinger served in a variety of senior level management roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. At Johnson & Johnson, Mr. Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was also a member of the Immunology R&D/ Commercial leadership team for Johnson & Johnson’s Worldwide Immunology Franchise. Prior to Johnson & Johnson, Mr. Grissinger spent 12 years at Ciba-Geigy in finance, marketing and business development roles. Mr. Grissinger also serves on the board of directors at Aprea Therapeutics (Nasdaq: APRE) and three privately-held biotechnology companies, Envisagenics, Inc., AnaCardio AB, and NephroDI Therapeutics, Inc. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
“I am pleased to join the Board of Adicet, a company rooted in harnessing the power of the immune system by developing off-the-shelf gamma delta CAR T cell therapies to make a meaningful difference in patients’ lives,” said Mr. Grissinger. “I look forward to working alongside the Board and management team and contributing to the advancement of current pipeline programs focused on autoimmune and oncology indications.”
Forward-Looking Statements
This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: expectations related to Adicet’s business development, strategic opportunities and growth; Adicet’s plans and expectations for advancing its autoimmune programs across multiple autoimmune and solid tumor indications; and the anticipated contribution of the members of Adicet’s Board of Directors to the Company’s business.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417817364/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What experience does Michael Grissinger bring to Adicet Bio's board (ACET)?
How will Michael Grissinger's appointment impact Adicet Bio's (ACET) strategic direction?
What other board positions does Michael Grissinger currently hold besides Adicet Bio (ACET)?
What is Adicet Bio's (ACET) main therapeutic focus?
